• Je něco špatně v tomto záznamu ?

CHEK2 variant I157T may be associated with increased breast cancer risk

O Kilpivaara, P Vahteristo, J Falck, K Syrjakoski, H Eerola, D Easton, J Bartkova, J Lukas, P Heikkila, K Aittomaki, K Holli, C Blomqvist, OP Kallioniemi, J Bartek, H Nevanlinna

. 2004 ; 111 (4) : 543-547.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc14079637

Cell cycle checkpoint kinase 2 (CHEK2) is a transducer of cellular responses to DNA damage. The CHEK2 1100delC has previously been shown to be a low-penetrance breast cancer susceptibility allele. We have evaluated the role of another CHEK2 variant, I157T in the FHA domain of the gene, for association with breast cancer. I157T was found at a significantly higher frequency in the population-based series of breast cancer patients (77/1035, 7.4%, odds ratio [OR] = 1.43, 95% confidence interval [CI] = 1.06-1.95, p = 0.021) than among population controls (100/1885, 5.3%). The frequency in the familial breast cancer patients was not elevated (28/507, 5.5%, OR = 1.04, 95% CI = 0.68-1.61). The I157T protein, that undermines cellular responses to ionizing radiation and shows deficiency in substrate recognition in vivo, was expressed at normal level in tumor tissues as well as in cultured cells. The I157T protein was stable and it dimerized with the wild-type CHEK2 co-expressed in human cells. These functional properties of the I157T protein suggest that this variant may have negative effect on the pool of normal CHEK2 protein in heterozygous carrier cells by formation of heterodimers with wild-type CHEK2. The I157T variant may be associated with breast cancer risk, but the risk is lower than for 1100delC. Copyright 2004 Wiley-Liss, Inc.

000      
00000naa a2200000 a 4500
001      
bmc14079637
003      
CZ-PrNML
005      
20141120105756.0
007      
ta
008      
141120s2004 xxu f 000 0|eng||
009      
AR
035    __
$a (PubMed)15239132
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kilpivaara, O. $u Department of Obstetrics and Gynecology, Helsinki University Central Hospital (HUCH), Helsinki, Finland.
245    10
$a CHEK2 variant I157T may be associated with increased breast cancer risk / $c O Kilpivaara, P Vahteristo, J Falck, K Syrjakoski, H Eerola, D Easton, J Bartkova, J Lukas, P Heikkila, K Aittomaki, K Holli, C Blomqvist, OP Kallioniemi, J Bartek, H Nevanlinna
520    9_
$a Cell cycle checkpoint kinase 2 (CHEK2) is a transducer of cellular responses to DNA damage. The CHEK2 1100delC has previously been shown to be a low-penetrance breast cancer susceptibility allele. We have evaluated the role of another CHEK2 variant, I157T in the FHA domain of the gene, for association with breast cancer. I157T was found at a significantly higher frequency in the population-based series of breast cancer patients (77/1035, 7.4%, odds ratio [OR] = 1.43, 95% confidence interval [CI] = 1.06-1.95, p = 0.021) than among population controls (100/1885, 5.3%). The frequency in the familial breast cancer patients was not elevated (28/507, 5.5%, OR = 1.04, 95% CI = 0.68-1.61). The I157T protein, that undermines cellular responses to ionizing radiation and shows deficiency in substrate recognition in vivo, was expressed at normal level in tumor tissues as well as in cultured cells. The I157T protein was stable and it dimerized with the wild-type CHEK2 co-expressed in human cells. These functional properties of the I157T protein suggest that this variant may have negative effect on the pool of normal CHEK2 protein in heterozygous carrier cells by formation of heterodimers with wild-type CHEK2. The I157T variant may be associated with breast cancer risk, but the risk is lower than for 1100delC. Copyright 2004 Wiley-Liss, Inc.
590    __
$a bohemika - dle Pubmed
650    12
$a nádory prsu $x etiologie $x genetika $7 D001943
650    02
$a studie případů a kontrol $7 D016022
650    02
$a checkpoint kinasa 2 $7 D064447
650    02
$a poškození DNA $7 D004249
650    02
$a replikace DNA $7 D004261
650    02
$a ženské pohlaví $7 D005260
650    02
$a tumor supresorové geny $7 D016147
650    12
$a genetická predispozice k nemoci $7 D020022
650    12
$a zárodečné mutace $7 D018095
650    02
$a lidé $7 D006801
650    02
$a imunohistochemie $7 D007150
650    02
$a odds ratio $7 D016017
650    12
$a protein-serin-threoninkinasy $x genetika $7 D017346
650    02
$a tolerance záření $7 D011836
700    1_
$a Vahteristo, P.
700    1_
$a Falck, J.
700    1_
$a Syrjakoski, K.
700    1_
$a Eerola, H.
700    1_
$a Easton, D.
700    1_
$a Bártková, Jiřina $7 xx0094304
700    1_
$a Lukáš, Jiří $7 xx0094305
700    1_
$a Heikkila, P.
700    1_
$a Aittomaki, K. $7 gn_A_00002739
700    1_
$a Holli, K.
700    1_
$a Blomqvist, C.
700    1_
$a Kallioniemi, OP..
700    1_
$a Bártek, Jiří, $d 1953- $7 xx0046271
700    1_
$a Nevanlinna, H.
773    0_
$t International Journal of Cancer $x 0020-7136 $g Roč. 111, č. 4 (2004), s. 543-547 $p Int J Cancer $w MED00002298
773    0_
$p Int J Cancer $g 111(4):543-7, 2004 Sep 10 $x 0020-7136
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20141120105837 $b ABA008
991    __
$a 20141120105837 $b ABA008
999    __
$a ok $b bmc $g 1047982 $s 878656
BAS    __
$a 3
BMC    __
$a 2004 $b 111 $c 4 $d 543-547 $x MED00002298 $i 0020-7136 $m International journal of cancer $n Int J Cancer
LZP    __
$a NLK 2014-1/lp

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...